Aemetis Receives FDA National Drug Code for OTC Sanitizer Products
Aemetis (NASDAQ: AMTX) announced FDA approval for the production and marketing of Over The Counter sanitizer products through its subsidiary, Aemetis Health Products. This registration allows Aemetis to meet the rising demand for hand sanitizers and related products during the COVID-19 pandemic, positioning the company as a unique large-scale sanitizer alcohol producer in the Western U.S. The global hand sanitizer market was valued at approximately $2.9 billion in 2019 and has seen significant growth due to the pandemic.
- FDA approval for production and marketing of sanitizer products.
- Positioned as the only large-scale producer of high grade sanitizer alcohol in the Western U.S.
- Ability to meet increasing demand for hand sanitizers and alcohol wipes.
- None.
Hand Sanitizer and Other Sanitizer Products to be Produced for Consumer Markets and to Fight COVID-19 Pandemic
CUPERTINO, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aemetis, Inc. (NASDAQ: AMTX), an advanced renewable fuels and biochemicals company that is a producer of high grade sanitizer alcohol, today announced that the Food & Drug Administration (FDA) has issued a National Drug Code (NDC) to Aemetis for the production and marketing of Over The Counter (OTC) sanitizer products.
“This FDA registration is an important step for Aemetis in the production and distribution of blended and packaged sanitizer alcohol products by our wholly-owned subsidiary, Aemetis Health Products,” stated Eric McAfee, Chairman and CEO of Aemetis, Inc. “Aemetis is in a unique position as the only large-scale producer of high grade sanitizer alcohol in the Western United States, and we plan to address the ongoing demand for hand sanitizer, alcohol wipes, and other sanitizer products under the Aemetis Health Products brand and on a private label basis.”
The global market for hand sanitizer and sanitizer products was approximately
About Aemetis
Headquartered in Cupertino, California, Aemetis is an advanced renewable fuels and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products by the conversion of ethanol and biodiesel plants into advanced biorefineries. Founded in 2006, Aemetis owns and operates a 65 million gallon per year ethanol production facility in California’s Central Valley near Modesto. Aemetis also owns and operates a 50 million gallon per year renewable chemical and advanced fuel production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India and Europe. Aemetis is building a biogas anaerobic digester network and pipeline to convert dairy animal waste gas to Renewable Natural Gas (RNG), and is developing a plant to convert waste orchard wood into high grade cellulosic alcohol. Aemetis holds a portfolio of patents and related technology licenses for the production of renewable fuels and biochemicals. For additional information about Aemetis, please visit www.aemetis.com.
Safe Harbor Statement
This news release contains forward-looking statements, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, expectations for growth in India and development of our cellulosic ethanol business in North America. Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “showing signs,” “targets,” “view,” “will likely result,” “will continue” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, demand for high grade alcohol and related products, including hand sanitizers, and other risks detailed in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020 and in our subsequent filings with the SEC. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.
| External Investor Relations Contact: Kirin Smith PCG Advisory Group (646) 863-6519 ksmith@pcgadvisory.com |
Investor Relations/
Media Contact:
Todd Waltz
(408) 213-0940
investors@aemetis.com
FAQ
What recent approval did Aemetis receive regarding sanitizer products?
How is Aemetis positioned in the sanitizer market?
What was the size of the hand sanitizer market in 2019?
How does Aemetis plan to distribute its sanitizer products?
What is the significance of the FDA registration for Aemetis?
